1ProLynx LOGO.png
ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie
March 25, 2024 09:00 ET | ProLynx Inc.
SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial...
1ProLynx LOGO.png
ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
February 05, 2024 09:00 ET | ProLynx Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors...
1ProLynx LOGO.png
ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors
January 24, 2024 09:00 ET | ProLynx LLC
SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc., a biotech company with a unique technology for tunable half-life extension of drugs, announced publication of a paper entitled “Could...
1ProLynx LOGO.png
ProLynx annonce le lancement d'un essai clinique de phase II sur son agent endommageant l'ADN, PLX038, chez des patientes atteintes d'un cancer de l'ovaire résistant au platine à la Mayo Clinic
October 07, 2022 13:57 ET | ProLynx LLC
SAN FRANCISCO, 07 oct. 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. a annoncé aujourd'hui que la première patiente a reçu le PLX038 (PEG~SN-38) dans le cadre d'un essai clinique de phase II sur le cancer...
1ProLynx LOGO.png
ProLynx kündigt den Beginn einer klinischen Phase-II-Studie mit dem DNA-schädigenden Wirkstoff PLX038 bei Patientinnen mit platinresistentem Eierstockkrebs an der Mayo Clinic an
October 07, 2022 13:57 ET | ProLynx LLC
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. gab heute bekannt, dass die erste Patientin in einer klinischen Phase-II-Studie zu platinresistentem Eierstockkrebs an der Mayo Clinic...
1ProLynx LOGO.png
ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic
October 07, 2022 09:00 ET | ProLynx LLC
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian...
1ProLynx LOGO.png
ProLynx nomme Richard King au poste de président-directeur général et Chris Ehrlich au poste de directeur du conseil d'administration
September 20, 2022 17:36 ET | ProLynx LLC
SAN FRANCISCO, 20 sept. 2022 (GLOBE NEWSWIRE) -- ProLynx, Inc., une société de biotechnologie dotée d'une nouvelle technologie de plateforme pour l'extension de la demi-vie des produits...
1ProLynx LOGO.png
ProLynx ernennt Richard King zum Chief Executive Officer und Chris Ehrlich zum Vorstandsmitglied
September 20, 2022 17:36 ET | ProLynx LLC
SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- ProLynx, Inc., ein Biotechnologieunternehmen mit einer neuartigen Plattformtechnologie für die Verlängerung der Halbwertszeit von Therapeutika,...
1ProLynx LOGO.png
ProLynxはRichard Kingを最高経営責任者(CEO)、Chris Ehrlichを取締役に任命
September 20, 2022 17:36 ET | ProLynx LLC
サンフランシスコ発, Sept. 21, 2022 (GLOBE NEWSWIRE) -- プロリンクス(ProLynx, Inc.)は、治療薬の半減期を延長するための新しいプラットフォーム技術を備えたバイオテクノロジー企業であり、斬新でクラス最高の治療法の開発を可能にするものであり、本日、MBAのリチャード・キング(Richard...
1ProLynx LOGO.png
ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director
September 20, 2022 06:00 ET | ProLynx LLC
SAN FRANCISCO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- ProLynx, Inc., a biotechnology company with a novel platform technology for half-life extension of therapeutics, enabling novel and potentially...